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ABSTRACT
Objective: The antineoplastic agent doxorubicin (DOX) is known for causing liver toxicity. Its metabolism in hepatocytes causes oxidative stress, which, 
in turn, induces DNA damage, lipid peroxidation, ATP depletion, and apoptosis. L-citrulline (CIT), a commonly found agent in fruits like watermelon, 
has piqued interest due to its antioxidant properties. In the body, CIT is converted to nitric oxide, which has been shown to mitigate hepatic injury 
by scavenging free radicals, improving hepatic sinusoidal microcirculation, and inhibiting neutrophilic infiltration. This study aims to investigate CIT 
ability to prevent DOX-induced hepatotoxicity.
Methods: A total of 20 Wistar rats were randomized to receive either DOX (10 mg/kg BW) or NaCl 0.9%. DOX-intoxicated group was further randomized 
to either received low-dose CIT (300 mg/kg BW), high-dose CIT (600 mg/kg BW), or aquadest. CIT was given orally for 6 days and DOX through 
intraperitoneal injection on days 4 and 5. Serum was obtained and hepatotoxicity was assessed with serum levels of aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT). Statistical analysis was done with one-way ANOVA and Tukey’s test.
Results: Serum ALT, AST, and GGT were increased significantly compared to that of normal group. CIT administration in both the doses could decrease 
the serum levels of ALT and AST significantly compared to that of DOX group. In this study, CIT in both the doses could reduce the serum levels of GGT 
compared to that of DOX group though not statistically significant.
Conclusions: This study suggests that CIT exerts hepatoprotective effect, as evident by the attenuation of serum biomarkers.
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INTRODUCTION
Doxorubicin (DOX), an anthracycline antibiotic, is a widely used 
antineoplastic agent with a well-established efficacy against many types 
of cancer, including breast, lung, gastric, ovarian, and thyroid cancers as 
well as lymphoma. However, its clinical use is limited due to its toxicity 
to healthy cells, affecting the heart, liver, brain, and kidneys [1,2].
Hepatotoxicity commonly results from DOX therapy. Overall, 30%–40% 
of patients receiving DOX injection had elevated serum levels of liver 
function biomarkers [3,4]. Moreover, DOX use increased the risk of 
developing liver injury, for example, acute/subacute liver necrosis, toxic 
hepatitis, and hepatic coma, by 1.29× across all types of cancer [5,6]. 
Metabolism of DOX in hepatocytes generates an abundance of free 
radicals, and the resulting oxidative stress induces DNA damage, lipid 
peroxidation, disturbance of membrane integrity, and ATP depletion, 
all of which culminate in apoptosis [1,7]. Currently, toxicity prevention 
only comprises dosage optimization and antioxidant supplementation. 
Further, no proposed hepatoprotective agent has been approved as a 
prophylactic drug against DOX-induced liver damage [3,8].
In this regard, L-citrulline (CIT), found in common fruits such as 
watermelon, has generated interest. A non-protein, non-essential 
amino acid, CIT, was previously thought to be a mere intermediate 
product of ureagenesis. However, in specific cells of the body, for 
example, periportal hepatocytes, renal cells, macrophages, and 
endothelial cells, CIT is recycled into L-arginine (ARG), from which 
nitric oxide (NO) is synthesized [9,10]. NO is shown to mitigate liver 
injury by improving hepatic sinusoidal microcirculation, inhibiting 
neutrophilic infiltration and cytokine production, and scavenging 
free radicals [11,12]. Remarkably, CIT is reportedly better than ARG 
in increasing NO bioavailability in the body [13,14]; this may be 
attributable to CIT-specific metabolism. Unlike ARG, CIT bypasses 
intestinal first-pass metabolism, thus reaching the systemic circulation 
in copious amounts [9,10].
An important role of CIT in NO metabolism demonstrates its potential 
to become a hepatoprotective agent. Only a few studies have evaluated 
CIT ability to maintain liver function [15,16]. Thus, the present study 
aimed to evaluate the hepatoprotective effects of CIT administration 
toward DOX-induced hepatotoxicity in animal models. We believe 
that this research will help in establishing CIT efficacy in ameliorating 
organ toxicity caused by DOX and other antineoplastic drugs, thus 




In total, 20 male Wistar rats (250–350 g) were used in this study. The 
rats were maintained under standardized conditions: Temperature, 
23°C; humidity, 55%; and light/dark cycle, 12/12 h. They were allowed 
to acclimatize 1 week before the initiation of the experiment. All rats 
had access to food and water ad libitum. This study was approved by 
the ethics committee in Indonesia (ethical clearance #0928/UN2.F1/
ETIK/2018).
Experimental design
This was an experimental laboratory study. The rats were randomly 
divided into four groups (n=4 rats/group) and received treatment 
throughout the 6-day experiment accordingly (Table 1). Determination 
of dosage was based on a study by Hayward and Hydock (for DOX) and 
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Yi et al. (for CIT) [17,18]. At the end of the experiment, the rats were 
euthanized with an intraperitoneal injection of ketamine (80 mg/kg 
BW) and xylazine (8 mg/kg BW). Supracardiac puncture was performed 
to euthanize the rats and collect blood samples.
The blood samples were stored in a plain tube without an anticoagulant, 
allowed to clot at room temperature (±28°C), and centrifuged at 
3000 rpm for 10 min. The separated supernatant, i.e. serum was 
collected in microtubes and stored at −80°C until needed.
Assessment of hepatotoxicity
Hepatotoxicity was assessed on the basis of aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), and gamma-glutamyl 
transferase (GGT) serum levels. Assays were performed using 
commercial diagnostic kits from DiaSys®, following the provided 
protocol. Serum biomarker activity is expressed in units/liter.
Statistical analysis
Data were analyzed using IBM SPSS Statistics version 22 and expressed 
as mean ± standard deviation. The Shapiro–Wilk test was used to 
assess data normality and Levene test to assess data variance. One-
way ANOVA test and Tukey’s multiple comparison test were used to 
determine differences between the treatment groups. Kruskal–Wallis 
test and Mann–Whitney U-test were performed in case of heterogeneity 
of variance. p<0.05 was considered to be statistically significant.
RESULTS
Effects of CIT administration on serum ALT activity of DOX-
intoxicated rats
DOX intoxication resulted in ×2.61 elevation of mean serum ALT activity, 
which was significantly higher compared with that in the normal group 
(p<0.05; Table 2, Fig. 1a). Concomitant administration of CIT with DOX 
resulted in significantly lower serum ALT activity compared with DOX 
alone (p<0.05), and this was observed for both the doses of CIT. High-
dose CIT administration decreased ALT activity significantly more than 
low-dose CIT (p<0.05), suggesting a dose-dependent effect.
Effects of CIT administration on serum AST activity of DOX-
intoxicated rats
DOX treatment caused a ×2.26 increase in serum AST levels, which 
was significantly higher than that in the normal group (p<0.05). 
Low-dose CIT administration with DOX only caused an insignificant 
reduction in AST levels in comparison with DOX administration alone 
(p>0.05). However, high-dose CIT administration with DOX resulted in 
significantly lower serum AST activity compared with administration of 
DOX alone (p<0.05). Further, there was a significant difference (p<0.05) 
between the low- and high-dose groups; hence, a dose-dependent effect 
of CIT may also exist (Table 2 and Fig. 1b).
Effects of CIT administration on serum GGT activity of DOX-
intoxicated rats
DOX treatment significantly elevated the levels of GGT in serum, with a 
mean activity that was ×7.93 higher than that observed in the normal 
group (p<0.05). Concomitant CIT administration, regardless of whether 
it was low or high dose, resulted in an insignificant decrease of mean 
serum GGT activity when compared with administration of DOX alone 
(p>0.05). While high-dose CIT administration lowered GGT level more 
than its low-dose counterpart, no statistically significant difference 
existed between the two (p>0.05; Table 2 and Fig. 1c).
DISCUSSION
In the present study, DOX intoxication of rats significantly elevated all 
serum biomarkers of liver function; this finding was expected and is 
consistent with those of previous studies. Dewanjee et al. reported that 
DOX-treated rats had increased serum AST, ALT, total cholesterol, and 
triglyceride levels accompanied with enhanced lipid peroxidation and 
increased apoptotic protein expression [19]. Damodar et al. reported 
that breast cancer patients undergoing DOX therapy had significantly 
increased AST, ALT, direct bilirubin, and total bilirubin levels from pre-
chemotherapy to the fourth cycle of chemotherapy [3].
The underlying mechanism for DOX-induced elevation of serum 
biomarkers is well documented. An abundance of reactive oxygen 
species (ROS) is produced when DOX is metabolized in hepatocytes, and 
the resulting oxidative stress causes DNA damage, lipid peroxidation, 
and disruption of membrane integrity. Further, ROS attacks inorganic 
phosphates, thus depleting hepatocytes of ATP and consequently 
triggering apoptosis. These events permit the escape of cytosolic 
enzymes, for example, ALT, AST, and GGT, from hepatocytes into the 
circulation, thereby increasing their serum levels [1,2,7,20].
Elevations of serum ALT and AST were significantly attenuated with 
concomitant administration of CIT, an effect better achieved with the 
high-dose administration (600 mg/kgBW). This finding is in agreement 
with those of other studies evaluating CIT hepatoprotective ability. 
Moussaoui et al. reported on rats with modeled ischemia/reperfusion 
injury and found that CIT treatment significantly reduced elevations of 
ALT and AST (p<0.05), along with lactate dehydrogenase, arginase, and 
intrahepatic myeloperoxidase activity [15]. In addition, Jegatheesan et al. 
identified a significant decrease of plasma ALT levels due to CIT in rats 
with fructose-induced liver steatosis. They also reported a decreased, 
although statistically insignificant, elevation of AST level (p>0.05) [16].
Table 1: Treatment groups and their respective regimen
Group I (normal) Days 1–6: Aquadest through gavage, ×1/day
*Days 4–5: As above+IP injection of 0.9% NaCl 
Group II (DOX) Days 1–6: Aquadest through gavage, ×1/day
*Days 4–5: As above+IP injection of DOX (10 mg/kg BW)
Group III (CIT low dose) Days 1–6: Oral low-dose CIT (300 mg/kg BW), ×1/day
*Days 4–5: As above+IP injection of DOX (10 mg/kg BW)
Group IV (CIT high dose) Days 1–6: Oral high-dose CIT (600 mg/kg BW), ×1/day
*Days 4–5: As above+IP injection of DOX (10 mg/kg BW)
CIT: L-citrulline, DOX: Doxorubicin, IP: Intraperitoneal
Table 2: Level of serum biomarkers of liver function across treatment groups¹
Serum levels I Normal II DOX III low-dose CIT IV high-dose CIT p-value
Serum ALT2 (U/L) 23.96±6.96a 62.67±11.96b 41.99±5.89c 35.02±3.14d <0.01
Serum AST (U/L) 39.68±5.22a 89.82±6.97b 83.81±9.87b 60.54±19.47a <0.01
Serum GGT2 (U/L) 1.09±0.45a 8.65±6.39b 4.31±4.27a 2.21±0.75a 0.026
ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, CIT: L-citrulline, DOX; Doxorubicin, GGT: Gamma-glutamyltransferase, U/L: Units/liter. 1Data are 
presented as mean±standard deviation. In a row, data labeled with different letters differ significantly (p<0.05). 2Heterogeneity of variance: Kruskal–Wallis test, followed 
by Mann–Whitney U-test, was performed 
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highly indicative of liver damage as ALT is found almost exclusively in 
hepatocytes [21]. Thus, its activity is considered a specific and sensitive 
indicator of hepatocellular damage. In addition, ALT is considered 
superior to AST in predicting hepatic injury among pre-clinical species 
such as rats and dogs [22,23]. AST, although found in hepatocytes, is 
also present in the heart, skeletal muscle, and kidneys, and thus, AST 
elevation is less specific for liver injury [21,23]. ALT elevation is usually 
more marked than AST elevation when the cause of elevation is hepatic 
due to longer half-life of ALT and higher proportion of AST bound to 
the mitochondria. Conversely, extrahepatic origin should be suspected 
when AST is more elevated than ALT [21-23]. The present study found 
greater ALT than AST elevation (×2.61 vs. ×2.26), confirming that DOX 
causes hepatocellular damage.
Furthermore, CIT capacity to significantly lower DOX-induced AST and 
ALT elevations in the present study demonstrates its hepatoprotective 
ability, which may be attributable to CIT antioxidative properties. 
Several studies have shown that CIT, as the precursor of ARG, potently 
increases NO levels in the body [13,14]. While we did not measure the 
NO levels following CIT administration in this study, we believe that CIT 
boosted NO production because NO is shown to scavenge superoxides 
and other free radicals, thereby mitigating oxidative stress caused 
by DOX metabolism in hepatocytes. Moreover, NO induces sinusoidal 
vasodilation, inhibits platelet aggregation, reduces neutrophilic 
infiltration, and inhibits cytokine release, all of which contribute to the 
mitigation of liver injury [11,12].
Introduction of CIT to DOX-intoxicated rats lowered the elevations of 
serum GGT, although insignificantly (p<0.05). Moussaoui et al. did not 
utilize GGT as part of their liver integrity assessment. However, they 
found that CIT significantly reduced elevations of all serum biomarkers, 
in which the present study failed to demonstrate [15]. Jegatheesan 
et al. used alkaline phosphatase (ALP), a marker of hepatobiliary 
injury similar to GGT; however, they also found that CIT only caused 
insignificant attenuation of ALP elevation [16].
Concentrated in the epithelial lining of bile ducts, GGT is an indicator of 
hepatobiliary injury. The findings of GGT support those of ALP, which 
is a more sensitive but less specific marker. GGT elevation also helps 
to confirm that elevations of AST and ALT are of hepatic origin [21,23]. 
Thus, decreased levels of GGT following the introduction of CIT as seen 
in this study also demonstrate CIT hepatoprotective ability.
CONCLUSIONS
The results of this study suggest that CIT applies a hepatoprotective 
effect, as evidenced by the attenuation of elevated serum biomarkers 
induced by DOX. The precise mechanism behind this must be further 
evaluated, especially in regard to the bioavailability of NO following the 
introduction of CIT, as previous studies have demonstrated NO ability 
in maintaining liver integrity. Nevertheless, using CIT, commonly 
found from food constituent, compensates organ toxicities induced 
by chemotherapeutic agents such as DOX may be a feasible clinical 
strategy.
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A liver function assessment using serum ALT and AST levels is 
frequently performed in the clinical setting. Elevated ALT level is 
Fig. 1: Histogram representing the mean serum activity of 
alanine aminotransferase (ALT) (a), aspartate aminotransferase 
(AST) (b), and gamma-glutamyl transferase (GGT) (c) across 
treatment groups. (a) Doxorubicin (DOX) treatment significantly 
elevated mean serum ALT activity and citrulline (CIT) treatment 
significantly attenuated DOX-induced ALT elevation in a dose-
dependent manner; (b) DOX treatment also significantly elevated 
mean serum AST activity and CIT only in a high dose was able 
to significantly attenuate DOX-induced AST elevation; (c) DOX 
treatment significantly elevated mean serum GGT activity and 
CIT treatment attenuate DOX-induced GGT elevation, although 
insignificantly. *p<0.05; ALT: Alanine aminotransferase, AST: 
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